Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Reports Initial Positive Data from US Trial of CD47 Candidate

publication date: Nov 11, 2020

Shanghai's I-Mab, reported positive initial results from a US Phase I trial of its CD47 treatment for relapsed or refractory solid tumors and lymphoma. The candidate, lemzoparlimab, was designed to lessen the toxicity of CD47 drugs by avoiding binding to red blood cells. In the trial, lemzoparlimab was well tolerated without dose-limiting toxicity or anemia. Next, it will be tested in combination with other drugs. In September, I-Mab announced a nearly $2 billion global partnership with AbbVie for lemzoparlimab. More details....

Stock Symbols: (NSDQ: IMAB) (NYSE: ABBV)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.